A5063335320- Parkinson's Disease Mechanisms and Treatments
- Neurological disorders and treatments
- Botulinum Toxin and Related Neurological Disorders
- Neurological diseases and metabolism
- Genetic Neurodegenerative Diseases
- Alzheimer's disease research and treatments
- Autism Spectrum Disorder Research
- Obsessive-Compulsive Spectrum Disorders
- Nuclear Receptors and Signaling
- Glycogen Storage Diseases and Myoclonus
- Olfactory and Sensory Function Studies
- Neurological and metabolic disorders
- Restless Legs Syndrome Research
- Neuroscience and Neuropharmacology Research
- Attention Deficit Hyperactivity Disorder
- RNA regulation and disease
- Neurology and Historical Studies
- Biochemical Analysis and Sensing Techniques
- Parkinson's Disease and Spinal Disorders
- Lysosomal Storage Disorders Research
- Genetics and Neurodevelopmental Disorders
- Neurotransmitter Receptor Influence on Behavior
- Cellular transport and secretion
- Advanced Neuroimaging Techniques and Applications
- Hereditary Neurological Disorders
National Hospital for Neurology and Neurosurgery
2016-2025
University College London
2016-2025
Radboud University Nijmegen
2024
Radboud University Medical Center
2024
Weston College
2014-2023
John Wiley & Sons (United States)
2018-2023
Queen Mary University of London
2012-2020
Wellcome Centre for Human Neuroimaging
2014-2020
Monash University
2007-2018
University College Hospital
1987-2018
Few detailed clinico-pathological correlations of Parkinson9s disease have been published. The pathological findings in 100 patients diagnosed prospectively by a group consultant neurologists as having idiopathic are reported. Seventy six had nigral Lewy bodies, and all these bodies were also found the cerebral cortex. In 24 cases without diagnoses included progressive supranuclear palsy, multiple system atrophy, Alzheimer9s disease, Alzheimer-type pathology, basal ganglia vascular disease....
We present a clinimetric assessment of the Movement Disorder Society (MDS)-sponsored revision Unified Parkinson's Disease Rating Scale (MDS-UPDRS). The MDS-UDPRS Task Force revised and expanded UPDRS using recommendations from published critique. MDS-UPDRS has four parts, namely, I: Non-motor Experiences Daily Living; II: Motor III: Examination; IV: Complications. Twenty questions are completed by patient/caregiver. Item-specific instructions an appendix complementary additional scales...
The micro-architecture of the substantia nigra was studied in control cases varying age and patients with parkinsonism. A single 7μ section stained haematoxylin eosin examined at a specific level within caudal using strict criteria. pars compacta divided into ventral dorsaltier, each tier further subdivided 3 regions. In 36 there linear fallout pigmented neurons advancing rate 4.7% per decade. Regionally, lateral relatively spared (2.1% loss decade) compared medial (5.4%) dorsal (6.9%). 20...
<b>Background: </b> A consensus conference on multiple system atrophy (MSA) in 1998 established criteria for diagnosis that have been accepted widely. Since then, clinical, laboratory, neuropathologic, and imaging studies advanced the field, requiring a fresh evaluation of diagnostic criteria. We held second 2007 present results here. <b>Methods: Experts aspects MSA were invited to participate 2-day conference. Participants divided into five groups, consisting specialists parkinsonian,...
Mutations in LRRK2, the gene that encodes leucine-rich repeat kinase 2, are a cause of Parkinson's disease (PD). The International LRRK2 Consortium was established to answer three key clinical questions: can LRRK2-associated PD be distinguished from idiopathic PD; which mutations pathogenic; and what is age-specific cumulative risk for individuals who inherit or at inheriting deleterious mutation LRRK2?Researchers 21 centres across world collaborated on this study. frequency common...
Polyunsaturated fatty acid (PUFA) levels (an index of the amount substrate available for lipid peroxidation) were measured in several brain regions from patients who died with Parkinson's disease and age-matched control human postmortem brains. PUFA reduced parkinsonian substantia nigra compared to other tissue. However, basal malondialdehyde (MDA; an intermediate peroxidation process) increased Expressing MDA terms content, difference between was even more pronounced. Stimulating production...
This article presents the revision process, major innovations, and clinimetric testing program for Movement Disorder Society (MDS)-sponsored of Unified Parkinson's Disease Rating Scale (UPDRS), known as MDS-UPDRS. The UPDRS is most widely used scale clinical study disease (PD). MDS previously organized a critique UPDRS, which cited many strengths, but recommended to accommodate new advances resolve problematic areas. An MDS-UPDRS committee prepared using recommendations published scale....
Many authorities have drawn attention to the difficulties in clinically distinguishing Parkinson9s disease (PD) from other parkinsonian syndromes. We assessed clinical features of 100 patients diagnosed prospectively by a group consultant neurologists as having idiopathic PD according their pathologic findings. Seventy-six percent these cases were confirmed PD. By using selected criteria (asymmetrical onset, no atypical features, and possible etiology for another syndrome) proportion true...
We have reviewed the clinical and pathological diagnoses of 143 cases parkinsonism seen by neurologists associated with movement disorders service at The National Hospital for Neurology Neurosurgery in London who came to neuropathological examination United Kingdom Parkinson's Disease Society Brain Research Centre, over a 10-year period between 1990 end 1999. Seventy-three (47 male, 26 female) were diagnosed as having idiopathic disease (IPD) 70 (42 28 another parkinsonian syndrome. positive...
Reduced glutathione (GSH) and oxidized (GSSG) levels were measured in various brain areas (substantia nigra, putamen, caudate nucleus, globus pallidus, cerebral cortex) from patients dying with Parkinson's disease, progressive supranuclear palsy, multiple-system atrophy, Huntington's disease control subjects no neuropathological changes substantia nigra. GSH reduced nigra (40% compared to subjects) GSSG marginally (29%) but insignificantly elevated; there other areas. The only significant...
SUMMARY Levels of iron, copper, zinc and manganese were measured by inductively coupled plasma spectroscopy in frozen postmortem brain tissue from patients with Parkinson's disease (PD), progressive supranuclear palsy (PSP), multiple system atrophy strionigral degeneration (MSA), Huntington's (HD) compared control subjects. Total iron levels found to be elevated the areas basal ganglia showing pathological change these disorders. In particular, total content was increased substantia nigra...
The reason for the high frequency of depression and anxiety in Parkinson's disease is poorly understood. Degeneration neurotransmitter systems other than dopamine might play a specific role occurrence these affective disorders. We used [11C]RTI-32 PET, an vivo marker both noradrenaline transporter binding, to localize differences between depressed non-depressed patients. studied eight 12 patients with without history matched age, duration doses antiparkinsonian medication. cohort had lower...
Neuropsychological tests known to reveal abnormalities in patients with frontal lobe damage were used explore cognitive function 30 mildly disabled, right-handed idiopathic Parkinson's disease. None of the had received treatment and all normal CT brain scans. Patients depression or high ischaemia scores excluded from study similar selection criteria for age-matched controls. No impairment general intellectual was found using WAIS New Adult Reading IQ no apparent on estimates two-choice...
<b>The authors studied the accuracy of clinical diagnosis idiopathic PD (IPD) in 100 consecutive clinically diagnosed cases that came to neuropathological examination. Ninety fulfilled pathologic criteria for IPD. Ten were misdiagnosed: multiple system atrophy (six), progressive supranuclear palsy (two), post-encephalitic parkinsonism (one), and vascular (one). Assessment features suggests an 90% may be highest can expected using current diagnostic criteria</b>.